Qishen Yiqi dropping pills plus conventional Western medicine improved efficacy in chronic heart failure patients.

A randomized controlled trial investigated the clinical efficacy of adding Qishen Yiqi dropping pills to conventional Western medicine treatment in patients with chronic heart failure. The study included 120 participants, comparing the combined intervention against conventional Western medicine treatment alone. The primary outcome assessed overall clinical efficacy, while secondary outcomes included cardiac function, exercise tolerance, quality of life, inflammatory markers, and adverse reactions.

The analysis revealed that the total effective rate was significantly higher in the study group receiving the combined therapy compared to the comparator group, with rates of 91.67% versus 70% respectively (p = 0.002). Regarding specific cardiac function parameters, the study group demonstrated a reduction in left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD), alongside an increase in left ventricular ejection fraction (LVEF).

Safety and tolerability data were not reported in the study, and no information regarding discontinuations or serious adverse events was provided. The study limitations include a relatively small sample size of 120 patients and the absence of reported data on exercise tolerance, quality of life, or inflammatory markers. Consequently, the evidence regarding the safety profile of this intervention remains incomplete. While the results suggest potential benefits for cardiac function and clinical efficacy, the lack of safety reporting and limited sample size necessitate cautious application of these findings in routine clinical settings.